ANASED- xylazine hydrochloride injection, solution

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

Xylazine Hydrochloride (UNII: NGC3S0882S) (Xylazine - UNII:2KFG9TP5V8)

Available from:

Akorn

INN (International Name):

Xylazine Hydrochloride

Composition:

Xylazine 20 mg in 1 mL

Administration route:

INTRAVENOUS

Prescription type:

PRESCRIPTION

Therapeutic indications:

Xylazine should be used in dogs and cats when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. Xylazine has been used successfully as follows: - Diagnostic procedures — examination of mouth and ears, abdominal palpation, rectal palpation, vaginal examination, catheterization of the bladder and radiographic examinations of head and extremities. - Orthopedic procedures, such as application of casting materials and splints. - Dental procedures. - Minor surgical procedures of short duration such as debridement, removal of cutaneous neoplasms and suturing of lacerations. - To calm and facilitate restraint of fractious animals. - Major surgical procedures: When used as a preanesthetic to general anesthesia. When used in conjunction with local anesthetics. - When used as a preanesthetic to general anesthesia. - When used in conjunction with local anesthetics.

Product summary:

20 mL multiple-dose vials containing 20 mg base activity per mL, List No. 4811. NDC 59399-110-20 NADA # 139-236, Approved by FDA

Authorization status:

New Animal Drug Application

Summary of Product characteristics

ANASED- XYLAZINE HYDROCHLORIDE INJECTION, SOLUTION
AKORN
----------
ANASED INJECTION
(xylazine injection)
Sterile Solution 20 mg/mL
Sedative and Analgesic For use in Dogs and Cats Only
CAUTION: Federal law restricts this drug to use by or on the order of
a licensed
veterinarian.
DESCRIPTION:
AnaSed is supplied as a sterile solution.
Each mL contains xylazine hydrochloride equivalent to 20 mg of base
activity,
methylparaben 0.9 mg, propylparaben 0.1 mg, and water for injection.
pH adjusted with
citric acid and sodium citrate.
INDICATIONS:
Xylazine should be used in dogs and cats when it is desirable to
produce a state of
sedation accompanied by a shorter period of analgesia. Xylazine has
been used
successfully as follows:
1. Diagnostic procedures — examination of mouth and ears, abdominal
palpation, rectal
palpation, vaginal examination, catheterization of the bladder and
radiographic
examinations of head and extremities.
2. Orthopedic procedures, such as application of casting materials and
splints.
3. Dental procedures.
4. Minor surgical procedures of short duration such as debridement,
removal of
cutaneous neoplasms and suturing of lacerations.
5. To calm and facilitate restraint of fractious animals.
6. Major surgical procedures:
a. When used as a preanesthetic to general anesthesia.
b. When used in conjunction with local anesthetics.
DOSAGE AND ADMINISTRATION:
1. Dosage
Intravenous — 0.5 mL/20 lb body weight (0.5 mg/lb or 1.1 mg/kg)
Intramuscular or Subcutaneous — 1.0 mL/20 lb body weight (1.0 mg/lb
or 2.2 mg/kg)
In large dogs (over 50 lbs) a dosage of 0.5 mg/lb administered
intramuscularly may
provide sufficient sedation and/or analgesia for most procedures.
Since vomiting may occur (see ADVERSE REACTIONS), fasting for 6 to 24
hours prior
to the use of xylazine may reduce the incidence; the I.V. route
results in the least
vomiting.
Following injection of xylazine, the animal should be allowed to rest
quietly until the full
®
®
effect has been reached.
These dosages produce sedation which is usually m